J. A. Ware

726 citations

23 papers · 599 indexed · h-index 10

Impact in

Genetics top 10%
- Chronic Lymphocytic Leukemia Research
Pharmaceutical Science top 10%
- Drug Solubulity and Delivery Systems

Papers in ⓘ

Molecular Biology 11
- PI3K/AKT/mTOR signaling in cancer 9
Pulmonary and Respiratory Medicine 11
- Lung Cancer Treatments and Mutations 7
- Advanced Breast Cancer Therapies 4

Co-authors: Mark J. Dresser (2 shared papers)Scott N. Holden (3 shared papers)Adam Frymoyer (1 shared paper)Leslie Z. Benet (1 shared paper)Nageshwar Budha (1 shared paper)Kathryn Mazina (7 shared papers)Johann S. de Bono (6 shared papers)Mika K. Derynck (6 shared papers)
Journals: Journal of Clinical Oncology (7 papers)Journal of Pharmaceutical and Biomedical Analysis (3 papers)International Journal of Mass Spectrometry (1 paper)Clinical Pharmacology & Therapeutics (1 paper)Diseases of the Colon & Rectum (1 paper)
Partner nations: United States France Sweden

In The Last Decade

J. A. Ware

22 papers receiving 577 citations

Peers

Countries citing papers authored by J. A. Ware

Since Specialization

Citations

This map shows the geographic impact of J. A. Ware's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by J. A. Ware with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites J. A. Ware more than expected).

Fields of papers citing papers by J. A. Ware

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by J. A. Ware. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by J. A. Ware. The network helps show where J. A. Ware may publish in the future.

Co-authors

The 25 scholars most cited alongside J. A. Ware, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with J. A. Ware Line = papers co-authored together J. A. Ware links everyone, so they are left out of the graph.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Showing the 20 most-cited of 23 papers — load more, or switch the sort, to bring in the rest.

#	Work
1	Drug Absorption Interactions Between Oral Targeted Anticancer Agents and PPIs: Is pH-Dependent Solubility the Achilles Heel of Targeted Therapy? Clinical Pharmacology & Therapeutics ·Nageshwar Budha, Adam Frymoyer, Gillian S. Smelick, Ji-de Jin, Marc R. Yago, Mark J. Dresser, Scott N. Holden, Leslie Z. Benet, J. A. Ware	2012	271
2	A first-in-human phase I study to evaluate GDC-0980, an oral PI3K/mTOR inhibitor, administered QD in patients with advanced solid tumors. Journal of Clinical Oncology ·Amy J. Wagner, Johanna C. Bendell, Saoirse Dolly, James P. Morgan, J. A. Ware, Jill Fredrickson, Kathryn Mazina, Jennifer Lauchle, Howard A. Burris, Johann S. de Bono	2011	60
3	A first-in-human phase I study to evaluate the pan-PI3K inhibitor GDC-0941 administered QD or BID in patients with advanced solid tumors Journal of Clinical Oncology ·Andrew J. Wagner, Dayna Hoff, Patricia LoRusso, Raoul Tibes, Kathryn Mazina, J. A. Ware, Y. Yan, Mika K. Derynck, George D. Demetri	2009	53
4	A phase I study evaluating the pharmacokinetics (PK) and pharmacodynamics (PD) of the oral pan-phosphoinositide-3 kinase (PI3K) inhibitor GDC-0941 Journal of Clinical Oncology ·Debashis Sarker, Rebecca Kristeleit, Kathryn Mazina, J. A. Ware, Yi Yan, Mark J. Dresser, Mika K. Derynck, Johann S. de Bono	2009	34
5	A phase I study evaluating GDC-0941, an oral phosphoinositide-3 kinase (PI3K) inhibitor, in patients with advanced solid tumors or multiple myeloma. Journal of Clinical Oncology ·Víctor Moreno, Richard D. Baird, Kinjal Shah, Bristi Basu, Nina Tunariu, Marı́a José Blanco, P. Cassier, J. V. Pedersen, M. Puglisi, Debashis Sarker, D. Papadatos-Pastos, A. Omlin, Andrea Biondo, J. A. Ware, Hartmut Koeppen, G. G. Levy, Kathryn Mazina, Johann S. de Bono	2011	33
6	A phase I dose-escalation study to evaluate GDC-0941, a pan-PI3K inhibitor, administered QD or BID in patients with advanced or metastatic solid tumors. Journal of Clinical Oncology ·Daniel D. Von Hoff, P. LoRusso, G. D. Demetri, Glen J. Weiss, Geoffrey I. Shapiro, Rajesh Ramanathan, J. A. Ware, Rajiv Raja, Jiangtao Jin, G. G. Levy, Kathryn Mazina, Amy J. Wagner	2011	25
7	A first-in-human, phase l study to evaluate the dual PI3K/mTOR inhibitor GDC-0980 administered QD in patients with advanced solid tumors or non-Hodgkin's lymphoma. Journal of Clinical Oncology ·Saoirse Dolly, Amy J. Wagner, J. C. Bendell, Y. Yan, J. A. Ware, Kathryn Mazina, Scott N. Holden, Mika K. Derynck, Johann S. de Bono, H. A. Burris	2010	21
8	A phase Ib study to evaluate the PI3-kinase inhibitor GDC-0941 with paclitaxel (P) and carboplatin (C), with and without bevacizumab (BEV), in patients with advanced non-small cell lung cancer (NSCLC). Journal of Clinical Oncology ·Benjamin Besse, Jean‐Charles Soria, Carlos Gomez‐Roca, J. A. Ware, Alex A. Adjei, Grace K. Dy, G. Shankar, R. Brachmann, Harry J.M. Groen	2011	18
9	Effect of indomethacin in autotransplanted colonic tumors Diseases of the Colon & Rectum ·Carlos Rubio-Terrés, B. G. Wallin, J. A. Ware, M. Sveander, A. Duvander	1989	16
10	Effects of Isotonic Fluid Load on Plasma Water and Extracellular Fluid Volumes in the Rat European Surgical Research ·Mats Larsson, J. A. Ware	1983	9
11	A solid phase extraction-liquid chromatographic–tandem mass spectrometry method for determination of concentrations of GDC-0941, a small molecule class I phosphatidylinositide 3-kinase inhibitor, to support clinical development Journal of Pharmaceutical and Biomedical Analysis ·Xiao Ding, Glenn Morrison, Brian Dean, Cornelis E. C. A. Hop, L. Tobler, Shaundel Percey, Meng Mei, Scott Reuschel, David A. West, Scott N. Holden, J. A. Ware	2011	9
12	Abstract P6-15-02: A Phase Ib Study Evaluating Safety, Tolerability, Pharmacokinetics (PK), and Activity of the Phosphoinositide-3 Kinase (PI3K) Inhibitor GDC-0941 in Combination with Trastuzumab-MCC-DM1 (T-DM1) in Patients with Advanced HER2-Positive Breast Cancer Cancer Research ·IE Krop, Antonio C. Wolff, EP Winer, KD Miller, BH Park, J. A. Ware, S. Holden, G. G. Levy, Mika K. Derynck, AM Storniolo	2010	8
13	1205 A first-in-human Phase I study to evaluate the pan-PI3K inhibitor GDC-0941 administered QD or BID in patients with advanced solid tumours European Journal of Cancer Supplements ·Daniel D. Von Hoff, Amy J. Wagner, P. LoRusso, Raoul Tibes, Jun Jin, J. A. Ware, Yiyi Yan, Mika K. Derynck, Marek Doležal, George D. Demetri	2009	7
14	A supported liquid extraction-LC–MS/MS method for determination of GDC-0980 (Apitolisib), a dual small-molecule inhibitor of class 1A phosphoinositide 3-kinase and mammalian target of rapamycin, in human plasma Journal of Pharmaceutical and Biomedical Analysis ·Xiao Ding, F. Li, Janine McKnight, C. Schmidt, K. Strooisma, Hisao Shimizu, Kathrin Faber, J. A. Ware, Brian Dean	2014	6
15	Phase 1B Study of Oral Dual-Pi3K/Mtor Inhibitor Gdc-0980 in Combination with Carboplatin (Carbo)/Paclitaxel (Pac) ± Bevacizumab (Bev) and Cisplatin (Cis)/Pemetrexed (Pem) in Patients (Pts) with Advanced Solid Tumors and Nsclc Annals of Oncology ·Emiliano Calvo, Valentina Boni, Rebecca S. Heist, Ursula A. Matulonis, Pasi A. Jänne, Omid Hamid, Esther Holgado, José Manuel Ordóñez, (unknown), Milijana Ugrenovic, Wen‐chang Lin, Bernard O'Keeffe, Mark R. Lackner, Jill M. Spoerke, J. A. Ware, Mary Pinder-Schenck	2014	6
16	Validation and determination of taselisib, a β-sparing phosphoinositide 3-kinase (PI3K) inhibitor, in human plasma by LC–MS/MS Journal of Pharmaceutical and Biomedical Analysis ·Xiao Ding, Kathrin Faber, Yifan Shi, Janine McKnight, Drew Dorshorst, J. A. Ware, Brian Dean	2016	5
17	1204 A Phase I study evaluating the pharmacokinetics (PK) and pharmacodynamics (PD) of the oral pan-phosphoinositide-3 kinase (PI3K) inhibitor GDC-0941 European Journal of Cancer Supplements ·R. Kristeleit, Debashis Sarker, Martin Förster, Martijn P. Lolkema, David Olmos, Kathryn Mazina, Martin Doležal, J. A. Ware, Yu Yan, Johann S. de Bono	2009	5
18	223 POSTER Pharmacokinetics and pharmacodynamic biomarkers for the pan-PI3K inhibitor GDC-0941: Initial Phase I evaluation European Journal of Cancer Supplements ·P. LoRusso, Debashis Sarker, Daniel D. Von Hoff, Raoul Tibes, Mika K. Derynck, J. A. Ware, Yu Yan, G. D. Demetri, Johann S. de Bono, Amy J. Wagner	2008	4
19	421 A Phase Ib study to evaluate the pan-PI3K inhibitor GDC-0941 with paclitaxel and carboplatin with and without bevacizumab in non-small cell lung cancer patients European Journal of Cancer Supplements ·Jean‐Charles Soria, Carlos Gomez‐Roca, J. A. Ware, Alex A. Adjei, R. Brachmann, Harry J.M. Groen	2010	4
20	Comparison of acetyl coenzyme A:arylamine N-acetyltransferase activity in the liver, kidney, and intestine of male and female rats from three strains. Drug Metabolism and Disposition ·J. A. Ware, Prasanna Divakaruni, Craig K. Svensson	1995	3

About J. A. Ware

J. A. Ware is a scholar working on Molecular Biology, Pulmonary and Respiratory Medicine, Oncology, Genetics and Hematology, having authored 23 papers that have together received 599 indexed citations. Recurring topics across this work include PI3K/AKT/mTOR signaling in cancer (9 papers), Lung Cancer Treatments and Mutations (7 papers), Cancer Treatment and Pharmacology (6 papers), Chronic Lymphocytic Leukemia Research (4 papers), Advanced Breast Cancer Therapies (4 papers), Cancer Genomics and Diagnostics (3 papers), Chronic Myeloid Leukemia Treatments (2 papers) and Monoclonal and Polyclonal Antibodies Research (2 papers). The work is most often cited by research in Genetics (130 citations), Pharmaceutical Science (49 citations), Oncology (218 citations), Pulmonary and Respiratory Medicine (215 citations) and Hematology (61 citations). J. A. Ware has collaborated with scholars based in United States, France and Sweden. Frequent co-authors include Mark J. Dresser, Scott N. Holden, Adam Frymoyer, Leslie Z. Benet, Nageshwar Budha, Kathryn Mazina, Johann S. de Bono, Mika K. Derynck, Amy J. Wagner and Y. Yan. Their work appears in journals such as Journal of Clinical Oncology, Journal of Pharmaceutical and Biomedical Analysis, International Journal of Mass Spectrometry, Clinical Pharmacology & Therapeutics and Diseases of the Colon & Rectum.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact